Siemens Healthineers stock tumbles after US bank downgrades rating to *Neutral*
Siemens Healthineers has faced a setback after Exane BNP Paribas downgraded its stock from Outperform to Neutral. The US bank also cut its price target for the company, though it remains above the current trading level. Meanwhile, the firm’s subsidiary, Varian, has announced a new partnership in cancer treatment.
Exane BNP Paribas lowered its rating for Siemens Healthineers, shifting from Outperform to Neutral. The US bank set a new price target of €48, down from previous expectations. Despite this adjustment, the target still sits above the stock’s current price of €42.90, indicating confidence in the business but reduced optimism about its growth compared to peers.
The downgrade triggered a 1.4% drop in Siemens Healthineers’ share price, leaving it trading near €42.90. Analysts at Exane BNP Paribas now favour other European medtech companies, naming Sartorius, Fresenius, EssilorLuxottica, and Straumann as their top sector picks. Sartorius received an upgrade to Outperform, while Fresenius was highlighted as a preferred investment.
The US bank predicts a two-speed year for the European medtech sector in 2026, with some stocks outperforming others. Siemens Healthineers, however, is struggling to win back large investors after the downgrade and the shift in focus toward competitors.
In separate news, Varian—a Siemens Healthineers company—has teamed up with Telix Pharmaceuticals. The partnership aims to develop combined theranostic and radiation therapy solutions for prostate cancer treatment. The collaboration signals ongoing innovation in the firm’s healthcare division, despite the recent stock challenges.
Siemens Healthineers now faces a more cautious outlook from investors after the downgrade. The stock’s new price target of €48 suggests limited upside potential in the near term, though the business model itself remains intact. At the same time, the Varian-Telix partnership highlights the company’s continued push into advanced cancer therapies.
